Risankizumab outperforms secukinumab at one year
A phase 3b study investigating the efficacy and safety of risankizumab compared to secukinumab showed positive results, with…
Novembre 11, 2020
Clascoterone cream 1% targets androgen receptors
The topical cream is the first acne drug with a new mechanism of action to win FDA approval…
An update on immunotherapy for melanoma
Until recently, the prospects for melanoma patients were bleak, but scientific breakthroughs have brought effective new treatment options…